Close
Find out more about why this project is needed.
Bispecific T cell antibodies have recently been funded in the NHS for treatment of relapsed/refractory multiple myeloma (RRMM). A survey by Leeds Clinical Trials Unit showed that of 62 hospitals that participated (31 transplant and 31 non-transplant centres), 47% had some experience with bispecific antibodies, but only 29% had used them for multiple myeloma. Of those with experience, 86% were transplant centres.
To ensure equitable access to these therapies, it will be important for non-transplant centres to be able to provide bispecific antibody therapy to reduce the distances patients need to travel for treatment.
The survey also identified the need for staff training, Standard Operating Procedures (SOPs) for managing adverse events, and logistical support for hospitalisation and pharmacy storage. It also highlighted concerns about restricted access to Intravenous Immunoglobulin (IVIg) therapy.
Who will benefit from the project
Initially patients who can access bispecifics will have had four prior lines of treatment and are triple-class exposed (PI, IMiD, and CD38 Mab). However, this project will set up structures to deliver bispecifics for a wider range of indications, as these treatments move to earlier lines and combination therapies. It will also improve access to clinical trials for bispecifics.
There is concern that patients in under-served groups cannot access treatments that are NICE approved promptly. Data shows that this may be particularly an issue with patients from non-white communities (Black and Asian), and those from low socio-economic backgrounds. Patients from a more deprived background or minority group are unlikely to travel for treatment. There is also concern that older patients who may be suitable may be hesitant to try bispecific treatments. Through our interventions, we will enable many hospitals to allow access to their local patients, reducing inequalities.